[{"address1": "101 Lindenwood Drive", "address2": "Suite 225", "city": "Malvern", "state": "PA", "zip": "19355", "country": "United States", "phone": "(484) 875-3192", "website": "https://www.annovisbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.", "fullTimeEmployees": 6, "maxAge": 86400, "priceHint": 2, "previousClose": 6.03, "open": 6.03, "dayLow": 5.6, "dayHigh": 6.24, "regularMarketPreviousClose": 6.03, "regularMarketOpen": 6.03, "regularMarketDayLow": 5.6, "regularMarketDayHigh": 6.24, "beta": 1.774, "forwardPE": -2.8421054, "volume": 242885, "regularMarketVolume": 242885, "averageVolume": 534675, "averageVolume10days": 220760, "averageDailyVolume10Day": 220760, "bidSize": 1100, "askSize": 800, "marketCap": 66358712, "fiftyTwoWeekLow": 4.79, "fiftyTwoWeekHigh": 22.49, "fiftyDayAverage": 7.8038, "twoHundredDayAverage": 9.46815, "currency": "USD", "enterpriseValue": 63221624, "floatShares": 8351687, "sharesOutstanding": 11171500, "sharesShort": 1476265, "sharesShortPriorMonth": 1452712, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.1321, "heldPercentInsiders": 0.25198, "heldPercentInstitutions": 0.11611, "shortRatio": 1.42, "shortPercentOfFloat": 0.1767, "impliedSharesOutstanding": 11171500, "bookValue": -0.305, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -47534080, "trailingEps": -5.14, "forwardEps": -2.09, "52WeekChange": -0.5775249, "SandP52WeekChange": 0.26238096, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "ANVS", "underlyingSymbol": "ANVS", "shortName": "Annovis Bio, Inc.", "longName": "Annovis Bio, Inc.", "firstTradeDateEpochUtc": 1580308200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e153bc75-9830-375d-bf5e-330db4df878a", "messageBoardId": "finmb_622711087", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.94, "targetHighPrice": 72.0, "targetLowPrice": 13.0, "targetMeanPrice": 33.5, "targetMedianPrice": 24.5, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 3136968, "totalCashPerShare": 0.281, "quickRatio": 0.644, "currentRatio": 1.604, "returnOnAssets": -1.6064999, "returnOnEquity": -5.66487, "freeCashflow": -19775112, "operatingCashflow": -35373744, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]